Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods

The USPTO published a patent application disclosing lipid nanoparticle (LNP) compositions and methods for delivering nucleic acids encoding therapeutic proteins to treat cancer. The claimed invention covers LNPs containing vectors or nucleic acids encoding peptide-based anticancer agents, along with methods for initiating, enhancing, or prolonging anti-tumor responses in subjects. The application names ten inventors including Eric J. Sorscher, James E. Dahlman, and Philip John Santangelo, and includes CPC classifications spanning nanoparticle drug carriers (A61K 9/5123), antibodies (C07K 16/2818), and gene delivery systems (C12N 15/88).

This is a patent application publication, not a regulatory requirement. No compliance actions are required. Inventors and researchers should review the disclosed claims for potential licensing opportunities. Pharmaceutical and biotech companies developing LNP-based gene therapies should monitor this application's prosecution for potential freedom-to-operate implications.